Highly Multiplexed Genotyping of Thiopurine S-Methyltransferase Variants Using MALDI-TOF Mass Spectrometry: Reliable Genotyping in Different Ethnic Groups
Authors:
Open Access
- 1 October 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 54 (10) , 1637-1647
Abstract
Background: To avoid severe hematotoxicity in patients, determination of the TPMT (thiopurine S-methyltransferase) genotype before commencing thiopurine therapy has become accepted.Keywords
This publication has 38 references indexed in Scilit:
- Explaining TPMT genotype/phenotype discrepancy by haplotyping of TPMT*3A and identification of a novel sequence variant, TPMT*23Pharmacogenetics and Genomics, 2007
- Novel Plexor™ SNP genotyping technology: comparisons with TaqMan® and homogenous MassEXTEND™ MALDI-TOF mass spectrometryHuman Mutation, 2007
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature, 2007
- Thiopurine Treatment in Inflammatory Bowel DiseaseClinical Pharmacokinetics, 2007
- MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide PolymorphismsClinical Chemistry, 2007
- Matrix-Assisted Laser Desorption/Ionisation, Time-of-Flight Mass Spectrometry in Genomics ResearchPLOS Genetics, 2006
- Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directionsOncogene, 2006
- Drug methylation in cancer therapy: lessons from the TPMT polymorphismOncogene, 2003
- Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprineGut, 2003
- Ethnic differences in thiopurine methyltransferase pharmacogeneticsPharmacogenetics, 1999